Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT02991651
Other study ID # IRX4204 NSCLC 1 01 2015
Secondary ID
Status Suspended
Phase Phase 1
First received
Last updated
Start date May 2016
Est. completion date December 31, 2024

Study information

Verified date March 2024
Source Io Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patient selection: a) Pathological confirmation of non-small cell lung cancer without activating EGFR mutations; b) Advanced stage disease (IV or IIIB with malignant effusion) with at least two prior chemotherapy regimens; c) No available curative therapy; d) Pregnant women are excluded; e) Informed consent. Pretreatment evaluation: a) Medical history and physical examination; b) Hepatic and renal function (bilirubin, aspartate aminotransaminase, creatinine); c) Preoperative staging evaluation including CT-chest or PET/CT scan; Treatment plan: Three dose levels of IRX4204 and erlotinib will be studied using intra-patient dose escalation for dose levels 1 and 2. These study agents will be administered orally until progression of disease, unacceptable toxicities, activation of a phase II study of the combination, or exhaustion of the IRX4204 drug supply. Evaluation on study: Adverse events will be graded on a scale of 0 to 5, using the Common Terminology Criteria for Adverse Events (CTCAE) v. 4.0. Efficacy will be assessed using the RECIST v1.1 criteria based on CT-chest or PET/CT scan after 8 weeks of study treatment.


Description:

Numerous studies in pre-clinical models and in human clinical trials have clearly established the potential for the use of rexinoids in the treatment and prevention of cancer. IRX4204, a second generation rexinoid, is a highly potent and specific activator of RXRs. Because IRX4204 is significantly more potent and more selective for the RXRs relative to the RARs than a first generation approved RXR agonist drug, bexarotene, it potentially will be associated with fewer adverse events and greater activity in clinical use. Preclinical studies of the combination of IRX4204 plus erlotinib, and previous clinical studies of the combination of the bexarotene plus erlotinib indicated at least additive beneficial effects for treatment of NSCLC. This study seeks to investigate the safety and activity of IRX4204 in combination with erlotinib in patients with previously treated advanced NSCLC.


Recruitment information / eligibility

Status Suspended
Enrollment 12
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients must have histologically or cytologically confirmed stage IV non-small cell lung cancer, or recurrent non-small cell lung cancer which is not amenable to curative intent therapy. - Documented disease progression on at least two prior lines of chemotherapy for advanced NSCLC. Progression within 6 months of adjuvant chemotherapy or definitive chemoradiation will count as one line of therapy. - Age =18 years. - ECOG performance status =2. - Ability to take pills by mouth. - Patients must have normal organ and marrow function as defined below: - Leukocytes =3,000/mcL - Absolute neutrophil count =1,500/mcL - Platelets =100,000/mcL - Hemoglobin =8.5 g/dL - Total bilirubin =1.5 x institutional upper limit of normal (ULN) - AST(SGOT)/ALT(SGPT) =2.5 × ULN or =5 x ULN if metastases to the liver - Creatinine clearance =40 mL/min - Patients with asymptomatic brain metastases are allowed, as long as they are stable and do not require treatment with anticonvulsants or escalating doses of steroids. Maximum daily dose of steroids should be prednisone 20 mg or equivalent. Radiation therapy for brain metastases must be completed at least 14 days prior to treatment on protocol. - Women of child-bearing potential and men must agree to use highly effective contraception (if using hormonal birth control must add a second barrier method; abstinence) prior to study entry, for the duration of study participation as well as for at least 1 month after the last dose of IRX4204. Men treated or enrolled on this protocol must also agree to use highly effective contraception prior to the study, for the duration of study participation and 3 months after completion of IRX4204 administration. - Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study. - Activating EGFR mutations detected in the tumor. - Prior treatment with an EGFR tyrosine kinase inhibitor. - Prior treatment with IRX4204 or another retinoid or rexinoid administered for the purpose of cancer treatment. Prior topical retinoid use is allowed. - History of allergic reactions attributed to IRX4204 or erlotinib or to compounds of similar chemical or biologic composition. - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Pregnant and nursing women. - Patients with a history of another active malignancy within the past two years, with the exception of non-melanoma cutaneous malignancy, cervical carcinoma in situ, or ductal carcinoma in situ which has been successfully treated with curative intent therapy. - Any gastrointestinal disorder expected to limit absorption of IRX4204 or erlotinib. - Patients with a history of active thyroid disease. However, patients with a history of hypothyroidism maintained in euthyroid state by supplementation with thyroid hormone, or a thyroid hormone containing preparation may be enrolled. - Patients taking coumarin-derived anticoagulants.

Study Design


Intervention

Drug:
IRX4204
RXR agonist
erlotinib
inhibitor of phosphorylation of the tyrosine kinase associated with the epidermal growth factor receptor

Locations

Country Name City State
United States Geisel School of Medicine at Dartmouth Lebanon New Hampshire

Sponsors (2)

Lead Sponsor Collaborator
Io Therapeutics Dartmouth College

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of co-administration of IRX4204 + erlotinib to determine recommended phase 2 dose based on number of participants experiencing treatment-related adverse events as assessed as grade 4 by CTCAE v4.0 To determine the recommended phase II dose (RP2D) for the combination of IRX4204 and erlotinib. 30 days
Secondary toxicity profile of the combination of IRX4204 and erlotinib based on number of participants experiencing treatment-related grades 1-4 adverse events as assessed by CTCAE v4.0 one month
Secondary disease control rate (defined as rate of stable disease + partial response + complete response) six months
Secondary progression free survival (PFS) six months
Secondary overall survival (OS) six months
Secondary response rate by RECIST 1.1 six months
See also
  Status Clinical Trial Phase
Recruiting NCT06003075 - Induction Chemo-Nivo in Unresectable Stage III NSCLC Phase 2
Enrolling by invitation NCT06293833 - Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan N/A
Recruiting NCT03705806 - Palliative Thoracic ImmunoRT
Not yet recruiting NCT06060964 - Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management Early Phase 1
Completed NCT04634630 - The Influence of Cancer Stem-cells on Risk of Relapse in Patients Harboring Adenocarcinoma and Squamous Cell Carcinoma of the Lung
Completed NCT03689634 - Move For Surgery - A Novel Preconditioning Program Phase 3
Recruiting NCT05537922 - I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Completed NCT03902834 - Move for Surgery (MFS): Evaluating the Use of Wearable Technology for Preconditioning Before Thoracic Surgery N/A
Active, not recruiting NCT03322072 - Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating N/A
Completed NCT02995889 - FLT-PET for Early Detection of Relapse in Patients With Irradiated Lung Cancer N/A
Recruiting NCT04237805 - A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients Phase 1/Phase 2
Terminated NCT05061940 - This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
Recruiting NCT05860296 - Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers Phase 1/Phase 2
Enrolling by invitation NCT04678440 - [18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients Early Phase 1
Recruiting NCT04222335 - Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients N/A
Recruiting NCT04415320 - X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases Phase 2
Recruiting NCT02786589 - Plasmodium Immunotherapy for Lung Cancer Phase 1/Phase 2
Recruiting NCT05085028 - A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Phase 3
Completed NCT05956782 - Breathe Easier II: A Dyad-based Multiple Behavior Intervention N/A
Enrolling by invitation NCT05863013 - Use of the ADL-Glittre Test in the Pre and Postoperative Period of Patients With Lung Cancer N/A